Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | BioNTech SE | 158 |
| 2 | Merck and Co Inc | 118 |
| 3 | Kao Corp | 104 |
| 4 | NOF Corp | 101 |
| 5 | Lipocine Inc | 94 |
| 6 | Lion Corp | 92 |
| 7 | Kimberly Clark Corp | 88 |
| 8 | Harvard University | 76 |
| 9 | Fujifilm Holdings Corp | 72 |
| 10 | Precision Biosciences Inc | 70 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 4,663 |
| 2 | A61P | Therapeutic activity (drug indications) | 3,122 |
| 3 | C12N | Microorganisms, enzymes | 1,823 |
| 4 | A61Q | Cosmetics, personal care | 1,039 |
| 5 | C07K | Peptides | 783 |
| 6 | C07D | Heterocyclic compounds | 574 |
| 7 | C07C | Acyclic and carbocyclic compounds | 508 |
| 8 | C07J | 377 | |
| 9 | G01N | Investigating / analysing materials | 329 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 290 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | 2001 | 1,763 | |
| IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | 2010 | Arbutus Biopharma Corp | 682 |
| Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | 2002 | 986 | |
| Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | 2005 | Lipocine Inc | 833 |
| Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions | 2003 | Lipocine Inc | 906 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 9 |
| 2017 | 9 |
| 2018 | 12 |
| 2019 | 15 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 10 |
| 2025 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Helena Gylling | University of Eastern Finland | 16 |
| 2 | Tore Midtvedt | Karolinska Institutet | 15 |
| 3 | Maarit Hallikainen | University of Eastern Finland | 8 |
| 4 | Aad Verrips | Canisius-Wilhelmina Ziekenhuis | 8 |
| 5 | Tatu A. Miettinen | University of Helsinki | 8 |
| 6 | Elisabeth Norin | Karolinska Institutet | 7 |
| 7 | Eran Leitersdorf | Hadassah Medical Center | 6 |
| 8 | Sarah Shefer | University Hospital, Newark | 6 |
| 9 | Helena Gylling | University of Eastern Finland | 6 |
| 10 | Gian Nicola Gallus | University of Siena | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| The origin of faeces by means of biomarker detection | 2002 | 405 | Toxic Organic Pollutants Impact |
| Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level | 2020 | 311 | Gut microbiota and health |
| Microflora‐associated characteristics in faeces from allergic and nonallergic infants | 2000 | 260 | Asthma and respiratory diseases |
| Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study | 1998 | 257 | Lipoproteins and Cardiovascular Health |
| Determination of endocrine-disrupting compounds in environmental samples using gas and liquid chromatography with mass spectrometry | 2002 | 241 | Pharmaceutical and Antibiotic Environmental Impacts |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Cholestan-3-ol?
How much patent activity involves Cholestan-3-ol, and what is the recent trend?
Which assignees hold the most patents related to Cholestan-3-ol?
What are the primary patent classification areas for Cholestan-3-ol inventions?
What research topics are covered in academic papers about Cholestan-3-ol?